Skip to main content
Rajesh Pahwa, MD, Neurology, Kansas City, KS

Rajesh Pahwa MD

Movement Disorder


Professor, Neurology, University Kansas School of Medicine

Join to View Full Profile
  • 3599 Rainbow BlvdKansas City, KS 66160

  • Phone+1 913-588-6970

  • Fax+1 913-535-2103

Dr. Pahwa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Rajesh Pahwa is a neurologist in Kansas City, KS and is affiliated with The University of Kansas Health System. He received his medical degree from Seth G.S. Medical College and has been in practice 34 years. He specializes in movement disorder and is experienced in parkinson's disease, deep brain stimulation and clinical trials.

Education & Training

  • University of Kansas School of Medicine
    University of Kansas School of MedicineResidency, Neurology, 1991 - 1992
  • Baylor College of Medicine
    Baylor College of MedicineResidency, Neurology, 1987 - 1991
  • Seth G.S. Medical College
    Seth G.S. Medical CollegeClass of 1983

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2021 - 2026
  • KS State Medical License
    KS State Medical License 1991 - 2025
  • Neurology
    American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Supernus Announces FDA Approval of ONAPGO™ (Apomorphine Hydrochloride) for Parkinson’s Disease
    Supernus Announces FDA Approval of ONAPGO™ (Apomorphine Hydrochloride) for Parkinson’s DiseaseFebruary 4th, 2025
  • Wren Builds Out Scientific Advisory Board for Neurodegenerative Diseases
    Wren Builds Out Scientific Advisory Board for Neurodegenerative DiseasesJanuary 4th, 2023
  • Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia with Levodopa
    Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia with LevodopaOctober 7th, 2021
  • Join now to see all

Committees

  • Member, Parkinson's Disease Practice Guidelines Committee

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: